Physician profile
Nga Molte
NPI 1114267853
$6,190.70
in general payments reported to CMS, 2019-2025
32 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $228 · 2021: $308 · 2022: $45.40 · 2023: $1,691 · 2024: $1,810 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,233.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,298.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $838.23 | 2021-2025 | |
| Lilly USA, LLC | $720.29 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $492.96 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.61 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $343.73 | 2019-2024 | Xarelto |
| Pfizer INC. | $226.76 | 2023-2025 | |
| Exact Sciences Corporation | $220.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $215.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $215.05 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.06 | 2023-2025 | Xifaxan |
| Dexcom, INC. | $152.34 | 2023-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $101.96 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $97.26 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $90.52 | 2023-2025 | Rexulti, Nuedexta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $89.61 | 2023-2025 | Trintellix |
| Astellas Pharma US INC | $77.53 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $60.44 | 2023 | Livalo, Seglentis |
| Idorsia Pharmaceuticals US INC | $56.46 | 2023 | Quviviq |
| Allergan, INC. | $50.67 | 2020 | |
| Sanofi-Aventis U.S. LLC | $45.20 | 2025 | |
| Daiichi Sankyo INC. | $33.42 | 2023 | Injectafer |
| Organogenesis INC. | $31.46 | 2024 | |
| Radius Health, INC. | $20.95 | 2025 | |
| Vivus LLC | $20.88 | 2025 | Qsymia |
| Regeneron Healthcare Solutions, INC. | $18.66 | 2025 | Evkeeza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.21 | 2025 | Caplyta |
| Philips North America LLC | $18.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.73 | 2023 | Austedo Xr |
| Merck Sharp & Dohme LLC | $15.82 | 2024 | Verquvo |
| Amarin Pharma, INC. | $14.75 | 2023 | |
| Paratek Pharmaceuticals, INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nga Molte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.